CLAIM #48643 · Pfizer Inc (PFE) · 2025Q3 earnings call · Nov 4, 2025 · due Dec 31, 2025
“As we kind of look forward on Vynda, we'll see some of these dynamics continue into Q4 as well, where we expect continued volume growth, but the 2 GTN drivers that I described will certainly impact our net sales, but Vynda is performing in the way that we expected.”
Aamir Malik · Executive
PENDING
graded after results covering Dec 31, 2025 are reported
Verify independently
SEC filings for PFE ↗ · Claim quote is verbatim from the 2025Q3 earnings call.